IO101 is a peptide vaccine encompassing an HLA-A2-restricted, 9 amino acid IDO-derived CD8+ T-cell epitope. IO101 was the basis for the discovery of IO102, a anti-cancer therapy containing a 21-mer IDO-derived peptide.
A first-in-man clinical phase I vaccination trial using IO101 was conducted. The study comprised 15 HLA-A2+ patients with advanced NSCLC who were vaccinated with IO101 in Montanide adjuvant following pre-treatment with topical Imiquimod (Aldara® Cream). The vaccine was well tolerated with manageable side effects and no CTCAE grade 3/4 toxicities.
One patient obtained an objective partial response after demonstrating continuous regression of liver metastases on vaccine treatment for 1 year.
Publications by founders